Hsbc Holdings PLC Sells 73,487 Shares of LifeStance Health Group, Inc. $LFST

Hsbc Holdings PLC trimmed its position in LifeStance Health Group, Inc. (NASDAQ:LFST) by 33.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 146,771 shares of the company’s stock after selling 73,487 shares during the quarter. Hsbc Holdings PLC’s holdings in LifeStance Health Group were worth $1,032,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Larson Financial Group LLC boosted its position in shares of LifeStance Health Group by 19,952.6% in the fourth quarter. Larson Financial Group LLC now owns 3,810 shares of the company’s stock worth $27,000 after purchasing an additional 3,791 shares during the period. Bayesian Capital Management LP bought a new stake in shares of LifeStance Health Group during the 2nd quarter valued at $52,000. Krane Funds Advisors LLC bought a new stake in shares of LifeStance Health Group during the 4th quarter valued at $71,000. Cibc World Markets Corp purchased a new position in shares of LifeStance Health Group during the 4th quarter valued at $77,000. Finally, Qtron Investments LLC purchased a new position in shares of LifeStance Health Group during the 4th quarter valued at $83,000. Institutional investors own 85.50% of the company’s stock.

Insider Activity

In other news, Director Eric Shuey sold 243,362 shares of LifeStance Health Group stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $8.02, for a total value of $1,951,763.24. Following the sale, the director directly owned 867,562 shares of the company’s stock, valued at approximately $6,957,847.24. The trade was a 21.91% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Robert Bessler sold 894,337 shares of the business’s stock in a transaction dated Friday, June 26th. The stock was sold at an average price of $10.13, for a total value of $9,059,633.81. Following the completion of the sale, the director owned 539,763 shares in the company, valued at $5,467,799.19. This represents a 62.36% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 7,762,394 shares of company stock worth $64,107,859 over the last 90 days. Corporate insiders own 3.50% of the company’s stock.

LifeStance Health Group Price Performance

Shares of NASDAQ:LFST opened at $10.88 on Tuesday. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.48 and a current ratio of 1.48. The firm has a fifty day moving average price of $8.74 and a 200 day moving average price of $7.56. LifeStance Health Group, Inc. has a fifty-two week low of $3.74 and a fifty-two week high of $11.62. The firm has a market cap of $4.22 billion, a price-to-earnings ratio of 181.33 and a beta of 1.12.

LifeStance Health Group (NASDAQ:LFST) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $0.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.01 by $0.03. The company had revenue of $403.48 million for the quarter, compared to the consensus estimate of $387.46 million. LifeStance Health Group had a net margin of 1.55% and a return on equity of 1.56%. The firm’s quarterly revenue was up 21.2% on a year-over-year basis. As a group, sell-side analysts expect that LifeStance Health Group, Inc. will post 0.12 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have issued reports on LFST shares. JPMorgan Chase & Co. increased their price target on LifeStance Health Group from $8.00 to $9.00 and gave the stock a “neutral” rating in a research note on Thursday, May 14th. Weiss Ratings restated a “hold (c-)” rating on shares of LifeStance Health Group in a research report on Wednesday, May 27th. Wall Street Zen raised LifeStance Health Group from a “buy” rating to a “strong-buy” rating in a research note on Saturday, July 4th. KeyCorp increased their target price on LifeStance Health Group from $11.00 to $13.00 and gave the stock an “overweight” rating in a research report on Monday. Finally, BTIG Research lifted their target price on LifeStance Health Group from $11.00 to $12.00 and gave the company a “buy” rating in a research note on Friday, May 8th. Two research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $10.25.

About LifeStance Health Group

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.